{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Bladder+Urothelial+Carcinoma&page=2", "query": { "condition": "Refractory Bladder Urothelial Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Bladder+Urothelial+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T03:42:34.165Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04579224", "title": "Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Bladder Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Refractory Bladder Urothelial Carcinoma", "Refractory Urothelial Carcinoma", "Stage IV Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Eribulin Mesylate", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Govitecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2021-06-28", "completion_date": "2030-08-15", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-10T03:42:34.165Z", "location_count": 450, "location_summary": "Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 307 more", "locations": [ { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04579224" }, { "nct_id": "NCT00406068", "title": "Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Bladder Neoplasms" ], "interventions": [ { "name": "Mycobacterial cell wall-DNA complex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bioniche Life Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2006-11", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2016-07-28", "last_synced_at": "2026-06-10T03:42:34.165Z", "location_count": 20, "location_summary": "Phoenix, Arizona • San Diego, California • New Britain, Connecticut + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00406068" }, { "nct_id": "NCT07322263", "title": "Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Non-Muscle Invasive Bladder Cancer (NMIBC)", "Urothelial Carcinoma", "Carcinoma in Situ (CIS)", "High-Grade Papillary Bladder Tumors", "BCG-Unresponsive Bladder Cancer", "Ta Stage Bladder Cancer", "T1 Stage Bladder Cancer", "BCG-Refractory Bladder Cancer", "High-Risk NMIBC", "Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)" ], "interventions": [ { "name": "Intravesical Gemcitabine and Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael A. O'Donnell", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 174, "start_date": "2026-04-10", "completion_date": "2033-01-01", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-06-10T03:42:34.165Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07322263" }, { "nct_id": "NCT02202772", "title": "Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma of the Urinary Bladder" ], "interventions": [ { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Guarionex J. Decastro", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2014-12-01", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-06-10T03:42:34.165Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02202772" }, { "nct_id": "NCT02769962", "title": "Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Urothelial Cancer", "Lung Neoplasms", "Small Cell Lung Cancer", "Prostate Cancer" ], "interventions": [ { "name": "EP0057", "type": "DRUG" }, { "name": "olaparib", "type": "DRUG" }, { "name": "CT scan", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest, abdomen, and pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone scan", "type": "DIAGNOSTIC_TEST" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "Echocardiogram", "type": "DIAGNOSTIC_TEST" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2016-05-09", "completion_date": "2025-03-04", "has_results": true, "last_update_posted_date": "2025-07-28", "last_synced_at": "2026-06-10T03:42:34.165Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02769962" }, { "nct_id": "NCT01780545", "title": "Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "OGX-427", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Noah Hahn, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2013-04", "completion_date": "2017-10", "has_results": true, "last_update_posted_date": "2022-07-11", "last_synced_at": "2026-06-10T03:42:34.165Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Duarte, California • Lancaster, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01780545" }, { "nct_id": "NCT01331824", "title": "Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Amrubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matthew Galsky", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-02", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2018-04-23", "last_synced_at": "2026-06-10T03:42:34.165Z", "location_count": 3, "location_summary": "Gilbert, Arizona • Indianapolis, Indiana • New York, New York", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01331824" }, { "nct_id": "NCT01200992", "title": "Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Neoplasm", "Neoplasm Recurrence, Local", "Transitional Cell, Carcinoma", "Carcinoma in Situ", "Mycobacterium" ], "interventions": [ { "name": "EN3348", "type": "BIOLOGICAL" }, { "name": "Mitomycin C", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bioniche Life Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2010-11", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-08-24", "last_synced_at": "2026-06-10T03:42:34.165Z", "location_count": 56, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01200992" }, { "nct_id": "NCT02844816", "title": "Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Bladder Urothelial Carcinoma", "Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage I Bladder Urothelial Carcinoma AJCC v6 and v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2017-03-13", "completion_date": "2024-06-26", "has_results": true, "last_update_posted_date": "2025-05-22", "last_synced_at": "2026-06-10T03:42:34.165Z", "location_count": 269, "location_summary": "Daphne, Alabama • Mobile, Alabama • Scottsdale, Arizona + 201 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02844816" }, { "nct_id": "NCT05052372", "title": "Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer", "Urothelial Carcinoma", "Transitional Cell Carcinoma", "Platinum-Resistant Urothelial Carcinoma", "Bladder Urothelial Carcinoma", "FGFR Mutation", "FGFR2 Gene Mutation", "FGFR3 Gene Mutation", "FGFR2 Amplification", "Locally Advanced Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Refractory Bladder Carcinoma", "Refractory Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "Balversa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "xCures", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-11-21", "completion_date": "2022-12-20", "has_results": false, "last_update_posted_date": "2022-12-22", "last_synced_at": "2026-06-10T03:42:34.165Z", "location_count": 1, "location_summary": "Raleigh, North Carolina", "locations": [ { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05052372" } ] }